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IMPROVING THE SENSITIVITY OF PHYSICAL FUNCTION
MEASURES IN RHEUMATOID ARTHRITIS: USE OF ITEM
RESPONSE THEORY IN PATIENTS TREATED WITH
ABATACEPT (CTLA4IG)
Martin M1, Emery P2, Kosinski M1,Ware J1, Li T3,Williams R4,
Maclean R3, Bjorner J1
1Quality Metric, Inc, Lincoln, RI, USA; 2University of Leeds, Leeds,
United Kingdom; 3Bristol-Myers Squibb, Princeton, NJ, USA;
4Bristol-Myers Squibb, Brussels, Belgium
OBJECTIVES: The Health Assessment Questionnaire (HAQ)
and the Modiﬁed HAQ (MHAQ) are examples of common
short-forms of physical function used to measure improvement
in the treatment of rheumatoid arthritis (RA) which have been
associated with ceiling problems. These problems, inherent to
short-form surveys, pose risks of failing to detect a treatment
response in clinical trials. Item Response Theory (IRT) methods
were used to examine the properties of two physical function
measures and construct a combined measure to better detect
changes in disease activity and treatment response. METHODS:
Data were from a 12-month, double-blind, multi-center study of
339 RA patients on a background of methotrexate randomized
to Abatacept at 2mg/kg, at 10mg/kg, or placebo. MHAQ and
SF-36 (with its Physical Functioning scale, PF10) were adminis-
tered at pretreatment and 3, 6, and 12 months post-treatment.
IRT methods were used to examine the surveys’ measurement
properties and compute new IRT-based physical function scores.
Analyses of variance were used to assess sensitivity to changes
in disease severity and treatment response. Relative validity coef-
ﬁcients were used to compare the measures. RESULTS: A Rasch
IRT model ﬁt the data. IRT-based scores successfully lowered the
ﬂoor and raised the ceiling of the physical function measured.
IRT-based scores were 30% more efﬁcient than MHAQ and
50% more efﬁcient than PF10 in discriminating among ACR
groups. In discriminating among treatment groups, IRT-based
scores were 25% more efﬁcient than MHAQ and 12% more efﬁ-
cient than PF10 at 6-months; and 16% and 17% more efﬁcient
at 12-months based on observed effect sizes. CONCLUSIONS:
Using IRT methodology to estimate a combined score for phys-
ical functioning lead to greater range of the construct measured.
The improved measure, with greater measurement precision and
sensitivity to treatment response, further conﬁrmed the beneﬁ-
cial effect of Abatacept on physical function in the treatment of
RA.
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REVALIDATION OF THE CEDARS-SINAI RHEUMATOID
ARTHRITIS HEALTH-RELATED QUALITY OF LIFE (CSHQ-RA)
SHORT FORM INSTRUMENT
Chiou CF1, Sherbourne C2, Cornelio IL3, Lubeck D3, Paulus H4,
Dylan M1,Weisman M5
1Zynx Health, A Cerner Company, Beverly Hills, CA, USA; 2RAND
Corporation, Santa Monica, CA, USA; 3Amgen, Inc,Thousand Oaks,
CA, USA; 4University of California, Los Angeles, Los Angeles, CA,
USA; 5Cedars-Sinai Health System, Los Angeles, CA, USA
OBJECTIVE: This study reassessed the psychometric perfor-
mance of the 11-item CSHQ-RA Short Form using a represen-
tative population of RA patients from 55 sites across the US.
METHODS: 307 of 309 screened patients from a 24-week mul-
ticenter, open-label, single arm study of RA patients receiving
anakinra completed the CSHQ-RA, the Medical Outcomes
Study Short Form-36 (MOS SF-36) and the Stanford Health
Assessment Questionnaire (HAQ) Disability Index. Data at
screening and baseline were used to examine the convergent
validity, discriminant validity, internal consistency, and test-retest
reliability. Convergent validity was tested, using Pearson’s cor-
relations, by comparing total score on the CSHQ-RA to those
from the Mental and Physical Component Summary (MCS and
PCS) of the MOS SF-36 and HAQ. ANOVA and Kruskal-Wallis
tests were used to assess the discriminant validity of the CSHQ-
RA. Internal consistency was measured by Cronbach’s alpha
coefﬁcient. Test–retest reliability was assessed using intraclass
correlation coefﬁcient (ICC). RESULTS: Response rate at base-
line was 95% (291). 81% of respondents were female; mean age
was 52 years (± 12); mean duration with RA was 10.8 years 
(± 10.4). Mean scores were CSHQ-RA Short Form 68.0 (± 16.0),
MCS 37.9 (± 10.9), PCS 31.2 (± 8.3), and HAQ 1.5 (± 0.7).
Pearson’s correlations with MCS, PCS, and HAQ were -0.69, 
-0.70, and 0.76 (P < 0.0001), respectively, demonstrating good
convergent validity. The difference in scores on the CSHQ-RA
Short Form of patients with different levels of physical disabil-
ity as measured by the HAQ was statistically signiﬁcant (P <
0.0001). Cronbach’s alpha coefﬁcient was 0.89, indicating good
internal consistency. Test-retest reliability was great with ICC
equal to 0.94. CONCLUSIONS: The results of this study
support the validity and reliability of the 11-item CSHQ-RA
Short Form as a measure that captures the impact of RA on
patients’ quality of life. Research to assess responsiveness and
clinically signiﬁcant change of the CSHQ-RA is under way.
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OBJECTIVES: Cox-2 selective inhibitors have been shown to
have similar efﬁcacy but a reduced gastrointestinal (GI) side-
effect proﬁle compared to non-selective non-steroidal anti-
inﬂammatory drugs (NSAIDs). The purpose of this study was to
use conjoint analysis (discrete choice methodology) to value the
reduction in risk of GI side effects with VIOXX (a Cox-2
inhibitor) when compared with non-selective NSAIDs in patients
with Osteoarthritis (OA). METHODS: Eighty-ﬁve participants
with OA were recruited for this project and asked to complete
questions regarding demographics, their OA and GI-related
symptoms and a discrete choice task. The attributes used in the
willingness-to-pay (WTP) scenarios included values for risks
associated with complicated perforations, ulcers and bleeds
(PUBs), uncomplicated PUBs, minor GI adverse and the cost of
medication to the patient. The risk estimates were derived from
clinical studies between VIOXX and non-selective NSAIDs.
RESULTS: Participants ranged in age from 49–83 years (mean
= 64.3 years). Twelve patients were excluded because they were
either non-traders (2) or irrational in their choice task (10),
leaving an effective sample size of 73. The total WTP for the
reduced risk of GI-complications provided by VIOXX, was
$A57.85 per month (95% CI:22.09–98.34). This included a
WTP of $A36.27 and $A38.43 for the reduced risk offered by
VIOXX of uncomplicated and complicated PUBs, respectively.
For minor GI events, the difference between the levels was not
statistically different from zero, indicating that no difference was
seen between the levels by the respondents. The point estimate
from this attribute produced a negative WTP (-$A16.85) that
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was included in the overall estimate of WTP. CONCLUSIONS:
The results from this study illustrate the value that OA patients
attribute to the reduction in GI-side effects associated with Cox-
2 selective inhibitors such as VIOXX. On average, patients were
willing to pay $A57.85 per month for a medication that specif-
ically reduced the risk of both complicated and uncomplicated
PUBs.
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BURDEN OF OSTEOARTHRITIS AND ITS TREATMENT 
ON PATIENTS
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OBJECTIVES: We describe pain level, medication use, potential
medication-related events, perceived medication effectiveness,
and medication switching among osteoarthritis (OA) patients.
METHODS: Patients totaling 4386 with self-reported OA com-
pleted an internet survey. Recent OA pain level was reported on
a 0–10 scale (10 = “worst possible” pain). Respondents reported
regular Rx and OTC medication use (~{!]~} 3x/wk), perceived
medication effectiveness, and frequency of 6 conditions possibly
associated with OA treatment(s) such as diarrhea, nausea/vom-
iting, heartburn, stomach pain, headache, and dizziness. Cate-
gorical frequencies were conservatively converted to continuous
variables (e.g., 1–3x a month = 1/month) to facilitate estimation.
Statistical comparisons were made using student’s t tests, X2, and
ANOVA. Logistic regression was used to identify predictors of
medication switching. RESULTS: Demographics: Mean age 55.3
years, 70.8% female, 91.4% white. Average recent OA pain was
4.9; 70.1% reported pain in 3 joints. 28.0%, 27.8%, and 32.2%
reported taking only OTC, only Rx, or both on a regular basis,
respectively. Twenty-ﬁve percent felt their OA medications were
slightly or not effective; 54.1% felt they were only moderately
effective. A total of 34.4% switched or discontinued medica-
tion(s) during the past year; 41.5% and 35.1% of these patients
cited lack of effectiveness and/or side-effects as a reason, respec-
tively. Respondents using both Rx and OTC OA medications
experienced potentially medication-related events more fre-
quently than those not taking medication. Patients who switched
OA medications reported experiencing higher recent OA pain,
GI events (compared to non-GI), pain in more than 6 joints, and
more than 3 events potentially related to medication use and
were more likely to be female (all p £ 0.05). CONCLUSIONS:
The burden of OA on patients in terms of pain, medication use,
and potential side effects is high. Only 1 in 4 patients in our
sample perceived their OA medications to be effective, and most
reported experiencing at least some OA pain despite regular
medication use.
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CONTRIBUTION OF PAIN, SITE OF PAIN AND NUMBER OF
JOINTS AFFECTED ON PRODUCTIVITY LOSS AMONG
WORKERS AND NON-WORKERS WITH OSTEOARTHRITIS
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OBJECTIVES: We examined productivity hours lost due to pain,
site of pain, and number of joints affected among workers and
non-workers with osteoarthritis (OA). METHODS: A total of
4386 self-reported OA patients completed an internet survey.
Respondents reported previous week’s work or daily activity
hours lost due to OA, OA pain (scale 0–10, 10 = “worst possi-
ble” pain over past 24 hours), site(s) of pain, and affected
joint(s). Impact of pain, number of affected joints, and site of
pain on total hours lost was evaluated using generalized linear
regression and including a pain level-employment interaction.
RESULTS: Demographics: mean age 55.3 years, 70.8% female,
91.4% white. Average recent OA pain was 4.9. Average hours
lost were 10.2 (SD 24.1). Non-workers reported more hours 
lost (18.2 vs. 1.7; p < 0.0001) and higher pain (5.4 vs. 4.5, 
p < 0.0001) than workers. Higher pain was associated with
increased lost hours for both groups, but more so for non-
workers (p < 0.0001). Both workers and non-workers with pain
in >7 joints lost signiﬁcantly more hours than those with fewer
affected joints (3.5 vs. 1.4 for workers, 31.6 vs. 14.1 for non-
workers, p < 0.0001). Lost hours were signiﬁcantly greater for
lower vs. upper body pain for both groups (1.5 vs. 0.5 for
workers, 10.9 vs. 5.6 for non-workers, p < 0.0001). Higher pain,
pain in >7 joints, low back pain, and pain-employment interac-
tion predicted hours lost due to OA (all p £ 0.05) after control-
ling for age, race, gender, education, employment, income, and
regular medication use. Speciﬁc joint sites did not predict lost
hours. The pain and pain-employment interaction parameters
indicate that non-workers lose more hours than workers at every
pain level and this differential increases with higher pain. CON-
CLUSIONS: Recent OA pain and the number of affected joints
but not individual pain site(s) impacted productivity. These
effects were greater for non-workers who likely have more severe
OA symptoms.
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It is well recognized that African-American (AA) patients with
knee osteoarthritis (OA) undergo total knee replacement (TKR)
at lower rates than their White (W) counterparts, OA. OBJEC-
TIVE: The purpose of this study was to evaluate the preferences
and beliefs of patients with knee OA from diverse ethnic back-
grounds in relation to TKR. METHODS: One hundred ninety-
eight patients with knee OA attending a health institution
participated in a survey; 67 were W, 66 AA and 65 Hispanic (H);
63% were female; mean age was 64.2 years. Patients were asked
if their physicians had recommended TKR, whether they had
thought about having the procedure, about their perceptions on
the beneﬁts and risks of TKR, and their potential expectations
if they were to undergo the procedure. RESULTS: A physician
had recommended TKR to 27% of AA, 15% of W and 11% of
H (p = 0.04). However, more W had considered undergoing
TKR: 42% v 30% AA and 25% H (p = 0.10); 97% of W, 85%
of AA and 75% of H reported that they would consider TKR if
their OA worsened and the procedure were recommended by
their physician (p = 0.002). Statistical differences were observed
in the perception of efﬁcacy across the groups: W were more
likely to consider TKR as a beneﬁcial procedure, and as an inter-
vention that could be helpful for them, compared to AA and H;
88% of W, 70% of AA and 57% of H had a close friend or rel-
ative who had undergone TKR (p = 0.001); these patients were
more likely to consider TKR than those who did not have rela-
tives or friends with TKR (p = 0.001). CONCLUSIONS: Ethnic
minority patients with knee OA are less likely to consider TKR,
preferences are associated with differences in perception of
